NASDAQ:GRFS - GRIFOLS S A/S Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Get Started
$22.23 -0.67 (-2.93 %)
(As of 06/21/2018 03:55 PM ET)
Previous Close$22.70
Today's Range$22.18 - $22.88
52-Week Range$19.92 - $25.18
Volume56,784 shs
Average Volume498,568 shs
Market Capitalization$15.43 billion
P/E Ratio20.64
Dividend Yield1.71%
Beta1.24
GRIFOLS S A/S logoGrifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. It offers plasma products, such as intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

Receive GRFS News and Ratings via Email

Sign-up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GRFS
CUSIPN/A
Webwww.grifols.com
Phone34-93-571-2200

Debt

Debt-to-Equity Ratio1.57
Current Ratio3.13
Quick Ratio1.36

Price-To-Earnings

Trailing P/E Ratio20.64
Forward P/E Ratio17.50
P/E Growth1.51

Sales & Book Value

Annual Sales$4.88 billion
Price / Sales3.11
Cash Flow$1.4250 per share
Price / Cash15.60
Book Value$6.02 per share
Price / Book3.69

Profitability

EPS (Most Recent Fiscal Year)$1.10
Net Income$749.04 million
Net Margins15.74%
Return on Equity18.28%
Return on Assets6.08%

Miscellaneous

Employees14,877
Outstanding Shares682,820,000

GRIFOLS S A/S (NASDAQ:GRFS) Frequently Asked Questions

What is GRIFOLS S A/S's stock symbol?

GRIFOLS S A/S trades on the NASDAQ under the ticker symbol "GRFS."

How often does GRIFOLS S A/S pay dividends? What is the dividend yield for GRIFOLS S A/S?

GRIFOLS S A/S announced a special dividend on Monday, May 28th. Shareholders of record on Monday, June 4th will be paid a dividend of $0.0125 per share on Tuesday, June 12th. This represents a dividend yield of 2.15%. The ex-dividend date is Friday, June 1st. View GRIFOLS S A/S's Dividend History.

When did GRIFOLS S A/S's stock split? How did GRIFOLS S A/S's stock split work?

Shares of GRIFOLS S A/S split on the morning of Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly issued shares were issued to shareholders after the market closes on Thursday, December 31st 2015. An investor that had 100 shares of GRIFOLS S A/S stock prior to the split would have 200 shares after the split.

What price target have analysts set for GRFS?

8 Wall Street analysts have issued 1 year target prices for GRIFOLS S A/S's stock. Their predictions range from $22.00 to $22.00. On average, they anticipate GRIFOLS S A/S's stock price to reach $22.00 in the next year. View Analyst Ratings for GRIFOLS S A/S.

Who are some of GRIFOLS S A/S's key competitors?

Who are GRIFOLS S A/S's key executives?

GRIFOLS S A/S's management team includes the folowing people:
  • Mr. Raimon Grifols Roura, Co-Chief Exec. Officer & Exec. Director (Age 54)
  • Mr. Ramón Riera Roca, COO, Chief Commercial Officer & Exec. Director (Age 63)
  • Mr. Tomás Dagá Gelabert, Vice Sec. & External Director (Age 62)
  • Mr. Víctor Grifols Deu, Co-CEO & Exec. Director (Age 41)
  • Mr. Alfredo Arroyo Guerra, CFO & Corp. VP (Age 60)

Has GRIFOLS S A/S been receiving favorable news coverage?

Media coverage about GRFS stock has been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. GRIFOLS S A/S earned a news sentiment score of 0.05 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 46.20 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are GRIFOLS S A/S's major shareholders?

GRIFOLS S A/S's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include AKO Capital LLP (1.71%), FIL Ltd (0.82%), Natixis (0.44%), Vaughan Nelson Investment Management L.P. (0.42%), Engadine Partners LLP (0.36%) and Artisan Partners Limited Partnership (0.34%). View Institutional Ownership Trends for GRIFOLS S A/S.

Which institutional investors are selling GRIFOLS S A/S stock?

GRFS stock was sold by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Farallon Capital Management LLC, JPMorgan Chase & Co., New York State Common Retirement Fund, Sei Investments Co., BlackRock Inc., Van ECK Associates Corp and Envestnet Asset Management Inc.. View Insider Buying and Selling for GRIFOLS S A/S.

Which institutional investors are buying GRIFOLS S A/S stock?

GRFS stock was purchased by a variety of institutional investors in the last quarter, including Natixis, FIL Ltd, Engadine Partners LLP, AKO Capital LLP, Millennium Management LLC, United Capital Financial Advisers LLC, Jane Street Group LLC and Thornburg Investment Management Inc.. View Insider Buying and Selling for GRIFOLS S A/S.

How do I buy shares of GRIFOLS S A/S?

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GRIFOLS S A/S's stock price today?

One share of GRFS stock can currently be purchased for approximately $22.18.

How big of a company is GRIFOLS S A/S?

GRIFOLS S A/S has a market capitalization of $15.43 billion and generates $4.88 billion in revenue each year. The biotechnology company earns $749.04 million in net income (profit) each year or $1.10 on an earnings per share basis. GRIFOLS S A/S employs 14,877 workers across the globe.

How can I contact GRIFOLS S A/S?

GRIFOLS S A/S's mailing address is AVINGUDA DE LA GENERALITAT 152-158 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 34-93-571-2200 or via email at [email protected]


MarketBeat Community Rating for GRIFOLS S A/S (GRFS)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  165 (Vote Outperform)
Underperform Votes:  222 (Vote Underperform)
Total Votes:  387
MarketBeat's community ratings are surveys of what our community members think about GRIFOLS S A/S and other stocks. Vote "Outperform" if you believe GRFS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GRFS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.